Drug Approval | April 06, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Pharma Solutions operates 10 research and development and/or production sites globally
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Subscribe To Our Newsletter & Stay Updated
